Trevi Therapeutics (TRVI) Liabilities and Shareholders Equity (2018 - 2026)

Trevi Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 67.85% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $780.7 million (up 116.5% YoY), while the FY2025 annual figure was $193.4 million, up 74.43% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $179.6 million, down from $193.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $208.3 million in Q2 2025, with the low at $30.4 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $107.0 million (2025), against an average of $116.8 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 306.26% in 2022, then slumped 32.4% in 2024.
• Trevi Therapeutics' Liabilities and Shareholders Equity stood at $123.0 million in 2022, then dropped by 27.32% to $89.4 million in 2023, then increased by 24.05% to $110.9 million in 2024, then jumped by 74.43% to $193.4 million in 2025, then fell by 7.15% to $179.6 million in 2026.
• Business Quant data shows TRVI's Liabilities and Shareholders Equity at $179.6 million in Q1 2026, $193.4 million in Q4 2025, and $199.4 million in Q3 2025.